NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/17/2026
Back to search
Official data from USPTO
MEIRAGTX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MEIRAGTX
ST13
US500000099023559Class
1, 5, 40, 42
Filing
99023559
Registration
8140892
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
02/17/2026
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
01/30/2025
Registration date
02/17/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/17/2026
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
London, GB
Examiner
REGAN, JOHN B
Law office
M40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
MeiraGTx Limited
Representatives
Michael J. Leonard Fox Rothschild LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
chemical additiveschemical auxiliary agentscarrierssubstancesall for use in the manufacture of pharmaceutical preparations
Class 5
pharmaceutical products for use in gene therapy; pharmaceutical preparations and substances for the treatment of neurological and neurodegerative diseasesocular diseases and rare diseasesin the nature of rare kidney diseasesrare cardiovascular diseasesrare hepato-gastro-enterological diseasesrare immunodeficienciesdevelopmental defectsneuromuscular diseasesrare neurological diseasesrare cardiovascular diseasesrare lung diseasesrare bone diseasesrare sensory disordersrare skin diseasesrare diseases of connective tissuerare endocrine diseasesrare hereditary metabolic diseasesrare nonmalignant hematologic disordersalivary gland conditionsoncologyautoimmune conditionsageingmetabolic diseaseobesity; auxiliary agents for pharmaceutical preparationssmall molecule compounds for use as drug delivery agents in pharmaceuticals; carriers for pharmaceutical preparationsdrug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; substances for pharmaceutical preparationsanti-infectivesanti-inflammatoriesantibacterial pharmaceuticalsantibioticsantifungal preparationsantivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical preparations and substances; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations and substances for ophthalmological use; pharmaceutical preparations and substances for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations and substances for the prevention and treatment of bone diseasessalivary gland conditionsoncologyautoimmune conditionsagingmetabolic diseaseobesity; biological preparations for use in cell cultures for medical purposes
Class 40
Custom manufacture of human therapeuticspharmaceuticalsbiologicals and biopharmaceuticals
Class 42
scientific research in the field of geneticsgene therapy and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; scientificbiologicalpharmaceutical and medical research services; laboratory research in the fields of geneticsdrug developmentbiotechnologymicrobiology and molecular biology; biochemical and biotechnological analysis services
Publications
History of USPTO decisions and trademark events.
20 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/17/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/30/2025
PUBO
PUBLISHED FOR OPPOSITION
12/30/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/24/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/02/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
11/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
11/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/15/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/15/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/15/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/21/2025
GNRT
NON-FINAL ACTION E-MAILED
07/21/2025
CNRT
NON-FINAL ACTION WRITTEN
07/21/2025
DOCK
ASSIGNED TO EXAMINER
07/10/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/01/2025
NWAP
NEW APPLICATION ENTERED
01/30/2025
MAFR
APPLICATION FILING RECEIPT MAILED
01/30/2025
Continuous trademark protection
Get notified about every new filing that threatens MEIRAGTX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.